Targeting the JNK Pathway for Therapeutic Benefit in CNS Disease

Title: Targeting the JNK Pathway for Therapeutic Benefit in CNS Disease

Volume: 1 Issue: 1

Author(s): Donna Bozyczko-Coyne, Michael S. Saporito and Robert L. Hudkins

Affiliation:

Keywords: CNS Disease, c-Jun N-terminal Kinase (JNK), Alzheimer, Parkinson, Huntington Diseases, stroke, mixed lineage kinase, (MLK), Inhibitors of, Stress-Activated Kinase Pathway

Abstract: The c-Jun N-terminal Kinase (JNK) pathway leading to c-Jun phosphorylation plays a causal role in apoptosis of isolated primary embryonic neurons and of multiple neuronal cell lines following a wide variety of stimuli. Activation of this pathway may also contribute to the neuronal atrophy and death that is associated with neurodegenerative pathological conditions including Alzheimers, Parkinsons, Huntingtons Diseases and stroke. Here, the data that providelinks between the activation of the JNK pathway and its potential to play an operative role in CNS disease are reviewed. Also included is the progress on development of inhibitors targeting the JNK pathway for therapeutic benefit.

Cite this article as:

Bozyczko-Coyne Donna, Saporito S. Michael and Hudkins L. Robert, Targeting the JNK Pathway for Therapeutic Benefit in CNS Disease, Current Drug Targets - CNS & Neurological Disorders 2002; 1 (1) . https://dx.doi.org/10.2174/1568007023339472